Differential Activation of Killer Cells in the Circulation and the Lung: A Study of Current Smoking Status and Chronic Obstructive Pulmonary Disease (COPD)

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wang, Jia ^a   Urbanowicz, Richard A ^a   Tighe, Patrick J ^a   Todd, Ian ^a   Corne, Jonathan M ^b   Fairclough, Lucy C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; KILLER CELL; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PROTEIN EXPRESSION; SMOKING; SPUTUM ANALYSIS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; KILLER CELLS, NATURAL; LUNG; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, KIR3DL1; SMOKING; SPUTUM;

EID: 84874852343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058556     Document Type: Article

References (38)

1. Celli BR, MacNee W, (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946.
2. Agusti A, Barnes PJ, (2012) Update in chronic obstructive pulmonary disease 2011. American journal of respiratory and critical care medicine 185: 1171-1176.
3. Knight DA, Yang IA, Ko FW, Lim TK, (2012) Year in review 2011: asthma, chronic obstructive pulmonary disease and airway biology. Respirology 17: 563-572.
4. Pauwels RA, Rabe KF, (2004) Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364: 613-620.
5. Mannino DM, Buist AS, (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-773.
6. Profita M, Riccobono L, Montalbano AM, Bonanno A, Ferraro M, et al. (2012) In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD. Immunobiology 217: 345-353.
7. Paats MS, Bergen IM, Hoogsteden HC, van der Eerden MM, Hendriks RW, (2012) Systemic CD4+ and CD8+ T-cell cytokine profiles correlate with GOLD stage in stable COPD. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 40: 330-337.
8. Siena L, Gjomarkaj M, Elliot J, Pace E, Bruno A, et al. (2011) Reduced apoptosis of CD8+ T-lymphocytes in the airways of smokers with mild/moderate COPD. Respiratory medicine 105: 1491-1500.
9. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC, (2010) Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respiratory research 11: 76.
10. Roos-Engstrand E, Pourazar J, Behndig AF, Blomberg A, Bucht A, (2010) Cytotoxic T cells expressing the co-stimulatory receptor NKG2 D are increased in cigarette smoking and COPD. Respiratory research 11: 128.
11. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC, (2009) Altered effector function of peripheral cytotoxic cells in COPD. Respiratory research 10: 53.
12. Fairclough L, Urbanowicz RA, Corne J, Lamb JR, (2008) Killer cells in chronic obstructive pulmonary disease. Clinical science 114: 533-541.
13. Ekberg-Jansson A, Andersson B, Avra E, Nilsson O, Lofdahl CG, (2000) The expression of lymphocyte surface antigens in bronchial biopsies, bronchoalveolar lavage cells and blood cells in healthy smoking and never-smoking men, 60 years old. Respir Med 94: 264-272.
14. Kim WD, Kim WS, Koh Y, Lee SD, Lim CM, et al. (2002) Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 122: 437-444.
15. Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA, et al. (1997) Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27: 71-76.
16. Parham P, (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201-214.
17. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, et al. (2002) Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3: 1142-1149.
18. Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
19. Parasa VR, Sikhamani R, Raja A, (2012) Effect of Recombinant Cytokines on the Expression of Natural Killer Cell Receptors from Patients with TB or/and HIV Infection. PloS one 7: e37448.
20. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 100: 4120-4125.
21. Lee JC, Lee KM, Kim DW, Heo DS, (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. Journal of immunology 172: 7335-7340.
22. Ferrini S, Cambiaggi A, Meazza R, Sforzini S, Marciano S, et al. (1994) T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol 24: 2294-2298.
23. Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, et al. (1990) Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 172: 1589-1598.
24. Patterson S, Chaidos A, Neville DC, Poggi A, Butters TD, et al. (2008) Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors. Journal of immunology 181: 3268-3276.
25. Phillips JH, Gumperz JE, Parham P, Lanier LL, (1995) Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268: 403-405.
26. Glader P, von Wachenfeldt K, Lofdahl CG, (2006) Systemic CD4+ T-cell activation is correlated with FEV1 in smokers. Respir Med 100: 1088-1093.
27. Leckie MJ, Jenkins GR, Khan J, Smith SJ, Walker C, et al. (2003) Sputum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+CD103+). Thorax 58: 23-29.
28. Roos-Engstrand E, Ekstrand-Hammarstrom B, Pourazar J, Behndig AF, Bucht A, et al. (2009) Influence of smoking cessation on airway T lymphocyte subsets in COPD. Copd 6: 112-120.
29. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC, (2009) Altered effector function of peripheral cytotoxic cells in COPD. Respir Res 10: 53.
30. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC, (2010) Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respir Res 11: 76.
31. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, et al. (2000) Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 15: 109-115.
32. Barnes PJ, (2004) Mediators of chronic obstructive pulmonary disease. Pharmacological reviews 56: 515-548.
33. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P, (2001) Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. Journal of immunology 166: 3933-3941.
34. McDonald DR, Goldman F, Gomez-Duarte OD, Issekutz AC, Kumararatne DS, et al. (2010) Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients. J Allergy Clin Immunol 126: 332-337, 337 e331-332.
35. Marquez ME, Millet C, Stekman H, Conesa A, Deglesne PA, et al. (2010) CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells. Cell Immunol 264: 86-92.
36. Lane N, Robins RA, Corne J, Fairclough L, (2010) Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin Sci (Lond) 119: 75-86.
37. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE, (1997) The use of induced sputum to investigate airway inflammation. Thorax 52: 498-501.
38. Crapo RO, Jensen RL, Hargreave FE, (2003) Airway inflammation in COPD: physiological outcome measures and induced sputum. Eur Respir J Suppl 41pp. 19s-28s.